DS0411 -

Elaboration of Functionalized Matrices for Uses in Skin Wound Healing and Regeneration – Healskin

Submission summary

Healskin is a collaborative program with complementary expertise conducted by three academic/clinical research teams and a private company, Silab. Our goal is to elaborate and develop natural and innovating biomaterials for tissue regeneration and wound healing. This new technology is based on the incorporation of active biomolecules in a 3D controlled porous matrix, made with natural polysaccharides that confer to these biomimetic functionalized 3D matrices an excellent biocompatibility and biodegradability and no toxicity. Our goal is (i) to evaluate the drug release properties from the scaffolds, (ii) to deeply investigate in vitro, on 2D and 3D models, and in vivo (zebrafish) their effect on skin reconstruction by analyzing regulation of matrix protein expression and of cell programs iii) to validate the efficiency of these functionalized 3D scaffolds and iv) to launch the industrial development.
The context is the healing and skin regeneration. Indeed, a wound generally consists of a break in the skin in which the deeper tissues such as the muscle and the bone may ormay not be damaged. Wound healing is an intrinsic body function by which the skin or another organ repairs itself after injury. It consists of a series of biochemical events, taking place within a highly orchestrated cascade, with the aim at replacing devitalized and missing cellular structures and tissue layers.
The world market for wound care — by 2021, the total wound market is projected to be worth over $18.5 billion, with an average 2013-2021 CAGR over 7%. The use of active compounds with biocompatible, biodegradable and tunable delivery systems is still an important bottleneck in research and development of healing strategies. HealSkin will tackle these major issues by providing wound care market with promising and innovative approaches for skin healing.
Project’s main goal is to develop functionalized matrices with healing properties, resulting in combination of innovative porous scaffolds matrices from Partner 1 (UMRS Inserm 1148, headed by Didier Letourneur, Paris) and active ingredients developed by Silab (Partner 2 - Brive). The consortium will also include 2 partners with worldwide expertise in the field of skin care and wound healing, UMR CNRS 5242 headed by Florence Ruggiero (Partner 3, ENS Lyon) and the dermatology department of CHRU of Besançon headed by Philippe Humbert (partner 4).
This project will place Silab, again, at the front of innovation in France in its domain and could open new opportunities and world markets for commercialization. Silab intends to industrialize and provide the market with ready-to-use functionalized matrices, in different forms and for different applications, according to HealSkin results. Academic partners will get strong benefits, as new co-owned IP will be formed, and scientific communication will be scheduled. This project is a real opportunity to start a long-term collaboration and to get this consortium persisting beyond the project scope.

Project coordination

Didier LETOURNEUR (Laboratoire de recherche vasculaire Translationnelle - Inserm)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.


Inserm U1148 Laboratoire de recherche vasculaire Translationnelle - Inserm
IGFL- CNRS Institut de Génomique Fonctionnelle de Lyon
CHRU Besançon Dermatologie - CHRU Besançon

Help of the ANR 399,947 euros
Beginning and duration of the scientific project: December 2016 - 36 Months

Useful links

Explorez notre base de projets financés



ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter